Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 12;11:11–24. doi: 10.2147/BLCTT.S245191

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Gupta et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

BCL-2 Family inhibitors and their targets. Venetoclax (ABT-199) is a BCL2 selective inhibitor and approved for use in CLL, SLL, and AML under the trade name VENCLEXTA^®. ABT-737 inhibits BCL2, BCLXL, and BCLW (not shown). Similar to ABT-737, Navitoclax inhibits BCL-2, BCLXL, and BCLW but is orally bioavailable. A-1155463 and A-1331852 are selective BCLXL inhibitors. There are five selective MCL1 inhibitors in early clinical trials: S64315 (MIK665), AZD5991, AMG176, AMG379, and ABBV467.